Latest

Axsome Therapeutics Surpasses $1 Billion Annual Run Rate with 52% Year-over-Year Growth in Commercial Portfolio

AXSM

Axsome Therapeutics Surpasses $1 Billion Annual Run Rate with 52% Year-over-Year Growth in Commercial Portfolio

Good morning, everyone. Welcome to Axsome's Third Quarter 2026 Earnings Conference Call. Axsome Therapeutics has announced a robust third quarter performance across its business, driven by continued commercial progress and advancements in its industry-leading neuroscience pipeline. The company's commercial portfolio generated $260 million in total revenue

By Amara Dubois